Related Experiment Video
Updated: Nov 21, 2025
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.8K
Oral GLP1 Analog: Where Does the Tide Go?
1Joslin Diabetes Center, Boston, MA, USA.
Clinical Medicine Insights. Endocrinology and Diabetes
|January 15, 2021
Summary
Oral semaglutide offers a promising new treatment for type 2 diabetes (T2D), obesity, and NAFLD. This review explores its impact on glycemic control, weight loss, and cardiovascular health.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes (T2D) is a leading cause of mortality, often preventable through lifestyle changes.
- Prediabetes awareness and prevention tools are insufficient among primary care physicians.
- Current diabetes medications have had limited success in reversing the epidemic.
Purpose of the Study:
- To review the first FDA-approved oral glucagon-like peptide-1 receptor agonist (GLP-1 RA), semaglutide.
- To discuss the potential impact of oral semaglutide on glycemic control, weight loss, and cardiovascular comorbidities.
- To examine factors influencing patient compliance, including cost, side effects, and clinical issues.
Main Methods:
- Review of existing literature on oral semaglutide.
- Analysis of clinical trial data regarding efficacy and safety.
- Examination of patient compliance factors.
Main Results:
- GLP-1 RAs, including injectable semaglutide, effectively reduce A1C and body weight.
- Certain GLP-1 RAs have demonstrated cardiovascular benefits in high-risk patients.
- Oral semaglutide shows potential for glycemic control, weight loss, and managing cardiovascular comorbidities.
Conclusions:
- Oral semaglutide represents a significant advancement in T2D treatment.
- The drug may also benefit patients with obesity and non-alcoholic fatty liver disease (NAFLD).
- Further research is needed to fully understand its long-term impact and patient adherence.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
592
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
592
01:06Oral Hypoglycemic Agents: Glinides
414
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
414
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
399
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
399
01:23Dipeptidyl Peptidase 4 Inhibitors
363
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
363
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
451
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
451
01:27Insulin Formulations: Types and Delivery
409
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
409